Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
Waldencast plc announced that the U.S. Food and Drug Administration (FDA) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. The approval adds to Waldencast’s injectable portfolio following the launch of Obagi® saypha® MagIQ™.
Obagi saypha ChIQ, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix delivered with high usable HA content at injection, consistent particle distribution, and predictable injection force and swelling profiles. It is indicated for use in cheek augmentation and correction of midface contour deficiencies in patients over the age of 21.
Obagi shared interim data from its Aesthetic Leadership with Obagi Hyaluronic Acid (ALOHA) Program, the largest real-world evaluation of a newly launched HA dermal filler to date. Reportedly, 94% of injectors believe Obagi saypha MagIQ complements their current filler options. The data also indicated that 42.6% of practices using the product have evaluated Obagi skincare, compared to industry data showing only 1 in 10 filler visits includes a professional skincare purchase.
Waldencast plc recently entered into an agreement to sell dermatological skincare business Obagi Medical to Bridgepoint.
